Tag: LaNova Medicines

LaNova Medicines and AstraZeneca have entered into an exclusive license agreement with  for LM-305, a pre-clinical stage antibody-drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).

LaNova Medicines, privately held biotech company headquartered in Shanghai, and LegoChem Biosciences, a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and the company's patented ADC technology platform* ConjuAll™, have signed a collaborative research agreement to evaluate a novel antibody-drug conjugate (ADC) candidate for an undisclosed target expressed in solid tumors.